Rislenemdaz
Product Specifications
UNSPSC Description
Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.
Target Antigen
iGluR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel;Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Rislenemdaz.html
Purity
99.86
Solubility
DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C(N1C[C@@H](F)[C@@H](CNC2=NC=CC=N2)CC1)OCC3=CC=C(C)C=C3
Molecular Weight
358.41
References & Citations
[1]Rachel Garner, et al. Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist. Pharmacol Res Perspect. 2015 Dec; 3(6): e00198.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-106441A/Rislenemdaz-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-106441A/Rislenemdaz-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
808732-98-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
